Small Molecule Drug Substance Outsourcing

In Q4 2020, ISR asked 123 outsourcers of small molecule API about the proportion of manufacturing allocated across three different approaches to outsourcing: tactical outsourcing, preferred providers, and strategic partnerships. The data show that the largest proportion of work is allocated tactically (38%), but that is expected to shift to preferred providers (41%) over the next three years as more outsourcers’ companies establish preferred relationships. To learn more, follow the link to the Small Molecule API CMO Quality Benchmarking report preview.